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resumo 
 
 
O presente trabalho relata as atividades realizadas no âmbito da coordenação 
de estudos clínicos durante o estágio curricular, inserido no Mestrado em 
Biomedicina Farmacêutica e desenvolvido no Hospital Infante D. Pedro, 
E.P.E., em Aveiro, Portugal. 
 
O estágio curricular decorreu no Serviço de Formação e Investigação e teve a 
duração de dez meses. Durante este período, elaborei três bases de dados 
que compilam a grande maioria dos ensaios clínicos, estudos observacionais e 
projetos de investigação clínica submetidos ao Hospital de Aveiro; realizei uma 
pesquisa bibliográfica e posterior organização da informação sobre a forma de 
um texto de revisão sobre o tema “qualidade das guidelines usadas na prática 
clínica em oncologia”; e participei em duas reuniões internacionais de 
investigadores. 
 
Nos primeiros meses de estágio, todo o trabalho realizado por mim era dirigido 
e supervisionado pela coordenadora do departamento de investigação. 
Gradualmente foi-me dada a oportunidade de realizar as diferentes tarefas 
autonomamente. Após alguns meses de treino, eu e a minha colega Diana 
Soares passámos a assegurar todo o trabalho relacionado com a investigação 
clínica. Fundamentalmente, o trabalho era focado na coordenação e realização 
de ensaios clínicos e estudos observacionais. Desta feita, acompanhei vinte 
ensaios clínicos e quatro estudos observacionais nos serviços de cardiologia, 
reumatologia, oncologia, endocrinologia e infeciologia.  
 
Durante o estágio curricular tive a oportunidade de realizar variadas tarefas 
que foram bastante úteis para o meu desenvolvimento enquanto profissional. 
Desempenhar as funções de uma coordenadora de estudos clínicos permitiu-
me aplicar o conhecimento e ferramentas adquiridas durante o Mestrado e, 
especialmente, permitiu-me realizar as diferentes tarefas de forma cada vez 
mais autónoma.  
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abstract 
 
The present work reports the activities of clinical studies coordination during the 
curricular training, inserted in Pharmaceutical Biomedicine Master’s degree, 
developed in Hospital Infante D. Pedro, E.P.E., in Aveiro, Portugal. 
 
The curricular training took place in Training and Research Service and it 
lasted for ten months. During this period, I developed three databases that 
compile the vast majority of clinical trials, observational studies and clinical 
research projects submitted to the Hospital of Aveiro; I performed a literature 
search and subsequent organization of the information in the format of a review 
text related to the theme “quality of oncology clinical practice guidelines”; and I 
attended two international investigator meetings. 
 
In the first months of the training, all my work was directed and supervised by 
the coordinator of the research department. Gradually, I was given the 
opportunity to perform the different tasks autonomously. After some months of 
training, my colleague Diana Soares and I became responsible for ensuring all 
work related to clinical research. Mainly, the work was focused on the 
coordination and conduction of clinical trials and observational studies. Thus, I 
followed twenty clinical trials and four observational studies in cardiology, 
rheumatology, oncology, endocrinology and infectious diseases departments. 
 
During the curricular training I had the opportunity to perform a wide range of 
activities that were very useful to my growth as a professional. Performing the 
tasks of a clinical study coordinator allowed me to apply all knowledge and 
tools acquired during the Master’s degree and, especially, it was very 
rewarding as it allowed me to perform the different activities in an increasingly 
autonomous way. 
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Chapter 1: Introduction 
Clinical research plays a key role in the progress of health, since it produces scientific evidence that helps 
health professionals in their daily clinical practice.1 
This training report is the compilation of all activities performed during the curricular training, carried out 
during the Pharmaceutical Biomedicine Master’s degree from Aveiro University and it was implemented in 
partnership with the training and research service (TRS) of Hospital Infante D. Pedro, E.P.E. (HIP), in Aveiro, 
Portugal. The curricular training started in the 6
th
 of September 2010 and ended in the 30
th
 of June 2011, 
thus lasting for ten months. 
In the first four months of the curricular training, all activities were performed under the orientation and 
guidance of my supervisor in the host institution, Dra. Maria Vale, the coordinator of the research 
department. After this period, I was allowed by my supervisor to perform the activities in an autonomous 
way. Starting in the 25th of February 2011, my colleague Diana Soares and I assured the continuation of the 
work undertaken by the TRS. 
During the curricular training period I had the opportunity to accompany all work performed to conduct and 
coordinate a clinical trial or an observational study, henceforth called clinical studies. It was possible to 
follow the evaluation process of the study site’s feasibility to participate in a specific clinical study, as well 
as the selection visits. It was also possible to observe how a clinical study is submitted to the administration 
board of HIP, which documents are needed to the submission and all steps done since the request arrives to 
the hospital and the study receives approval to initiate. After approval, I could follow the development of 
the studies and all the important steps in their management: study site initiation visits; screening of 
potential subjects, randomization of subjects, completion of the different study visits and study procedures, 
handling of study drug (if applicable), notification of adverse events (AE) and serious adverse events (SAE) 
and so on. In this curricular training, it was also possible to participate in the close out phase of some 
studies. Additionally, I attended a training course on “Clinical Research Training”, participated in two 
international investigator meetings and created three databases. 
This curricular training report is organized in five chapters. First, a description of the state of the art, the 
characterization of the host institution and the curricular training objectives are presented. Following this, 
the generic training attended in the host institution/external institutions is presented. Then, the description 
of the specific training performed in the TRS is exposed. This section includes the description of the 
followed clinical studies during the period of my curricular training. The fourth chapter presents the 
discussion of the curricular training and is ensued by the last chapter, with the conclusions. 
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1. State of the art 
The International Conference on Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) has published several important guidelines for the conduction of 
clinical trials. According to the ICH Topic E 6 guideline, a clinical trial (an interventional study) is “any 
investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other 
pharmacodynamics effects of an investigational product(s) (IP), and/or to identify any adverse reactions to 
an investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of an 
investigational product(s) with the object of ascertaining its safety and/or efficacy”.2 A short description of 
the principal aims of different types of clinical trials is provided in Table 1.  
Table 1. Brief description of the main aims of different types of clinical trials.3 
Type Aims 
Treatment Trials 
- Assess the efficacy and safety of a new IP or medical device for a specific therapeutic 
indication or for a new therapeutic indication; 
- Assess the efficacy and safety of new doses of an IP already in use; 
- Compare the efficacy and safety of IP or medical devices; 
- Evaluate if the new IP or medical device is more effective and safe than the standard 
medicinal product or medical device. 
Prevention trials 
- Look for better ways to prevent disease in people who have never had the disease or 
to prevent a disease from returning. 
Diagnostic trials - Find better tests or procedures for diagnosing a particular disease or condition. 
Screening trials - Test the best way to detect certain diseases or health conditions. 
Quality of life 
trials 
- Explore ways to improve comfort and the quality of life for individuals with a chronic 
disease (also known as supportive care trials). 
Adapted from “Glossary of clinical trials terms”. 
 
Clinical trials are commonly classified into four phases, each one with a specific goal, as presented below:3 
 Phase I – To find the maximum tolerated dose. To determine the metabolic and pharmacological 
actions; 
 Phase II – Initial effectiveness trial. To evaluate effectiveness, determine the short-term side 
effects and identify common risks; 
o Phase IIa assess the amount of drug to be given to the subject for optimal results; 
o Phase IIb assess how well the drug works at the prescribed dosage levels; 
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 Phase III – Efficacy trials. To obtain additional information about the effectiveness and evaluate the 
overall risk-benefit ratio; 
 Phase IV – Post-marketing surveillance for toxicity. To monitor ongoing safety in large populations 
and identify additional uses. 
Nowadays, a phase 0 could be also considered. In this phase, sub-therapeutic doses are used to support the 
performance of first-in-human tests. These studies are designed to speed up the development of promising 
medicinal products.4 
According to Decree-Law no. 46/2004, an observational study (a non-intervention study) is a “study in 
which medicines are prescribed according to the stipulated conditions in the marketing authorization 
application; not determined by a study protocol but according to medical practice; the decision to prescribe 
the medicine is not related to the decision to enrol a participant in the study; [in which] any other 
complementary diagnostic or evaluation procedure is not performed to participants; and [in which] 
epidemiological methods are used to analyse the collected data”.5 
There are several professionals involved in the design and conduction of a clinical study. The sponsor is the 
responsible for the design, implementation, management or financing the clinical study.5 Then, during the 
conduction and conduction of the clinical study, in addition to the sponsor, monitors and research team are 
involved. Monitors are responsible for supervising the clinical study evolution, as well as, for the verification 
of the data collected.2 Each clinical study is managed by a research team, which can include medical doctors 
(known as principal investigator, the PI, and sub-investigators), pharmacists, nurses, laboratory technicians, 
study coordinators and diagnosis and therapeutic technicians. The research team closely monitors the 
health of the clinical trial subjects and conduct the study in the study site. A schematic representation of 
the relationships established between the research team, the monitor and the sponsor is presented below 
(Figure 1). 
 
Figure 1. Schematic representation of the relations established between sponsor, monitor and research 
team. 
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The research team works together to ensure that all study procedures are met and that the health and well-
being of the participants are not compromised. All elements of the research team must sign and date the 
delegation log. This document determines the responsibilities of each element. The PI is the maximum 
responsible for the: (1) conduction of the trial at the study site; (2) research team and (3) responsibilities 
that were delegated on every member of the research team. The PI must ensure that all the elements of 
the research team are familiarized with the study protocol and with their particular responsibilities. Each 
element of the research team has different responsibilities in the trial, as is schematized in Figure 2.  
 
Figure 2. Schematic representation of the relations established between the different elements of the 
research team and main responsibilities of each element(s). Abbreviations: ICF – informed consent form; 
CRF – case report form; DCF – data clarification forms; IP – investigational product. 
 
All elements of the research team should be aware of, and should comply with, good clinical practice (GCP) 
principles. According to ICH Topic E 6 Guideline for Good Clinical Practice, GCP principles are “a standard for 
the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials 
that provides assurance that the data and reported results are credible and accurate, and that the rights, 
integrity, and confidentiality of trial subjects are protected”.2 All elements of the research team have to 
receive qualified training in ICH-GCP principles. 
 
The fundamental document of an ethical clinical research is the informed consent form (ICF). Obtaining 
informed consent is “a process by which a subject voluntarily confirms his or her willingness to participate 
in a particular trial, after having been informed of all aspects of the trial that are relevant to the subjects’ 
decision to participate. Informed Consent is documented by means of a written, signed and dated informed 
consent form”.2 The ICF has to be obtained before any study procedure is performed. 
1. Inform subject/obtain ICF 
2. Determine subject eligibility 
3. Perform key trial measurements 
4. Medical assessments 
5. Make CRF entries and corrections 
6. Resolve DCF 
7. Review and sign CRF 
8. Receipt and storage of IP 
9. Dispensation and accountability of IP 
10. Take blood/lab samples 
11. Obtain/confirm the diagnosis 
12. Process blood/lab samples 
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During the obtainment of the ICF, subjects are given detailed information about the study, including 
information about the purpose of the study, the tests and other procedures that will be required and the 
possible benefits and harms of taking part in the study. Subjects who agree to take part in the study are 
asked to sign and date the ICF and anyone can choose to leave the study at any time. The informed consent 
process continues throughout the study. In fact, if new benefits, risks or side effects are discovered during 
the course of the study, the investigators must inform the participants so they can decide whether or not 
they want to continue to take part in the study. In this situation, participants who want to continue in the 
study may be asked to sign and date a new version of the ICF. There are some particular situations to be 
considered when the investigator obtains the ICF: underage subjects, subjects incapable of giving his or her 
informed consent and illiterate subjects. In case of underage subjects or subjects incapable of giving their 
consent, the consent should be given by their legal representatives. In case of an illiterate subject, two 
witnesses (anyone that is not study related) should be called in order to sign and date the ICF.5 
National and international regulations and policies have been developed to ensure that clinical research is 
conducted according to strict scientific and ethical principles. In Table 2, the main national and international 
applicable laws and regulations are presented. 
Table 2. Main national and international regulatory framework for clinical research: references and brief 
description. 
Main regulatory frame Brief description 
European laws and regulations 
Declaration of Helsinki6 Ethical Principles for Medical Research Involving Human Subjects. 
ICH Topic E 62 Guideline for Good Clinical Practice. 
Directive 2001/20/EC, 
4th of March 20017 
Related to the approximation of laws, regulations and administrative 
provisions of Member States relating to the implementation of GCP in 
the conduct of clinical trials of medicinal products for human use. 
National laws and regulations 
Law no.46/2004, 19th August 20045 
Approves the conduct of clinical trials of medicinal products for 
human use. 
Law no.67/98,26
th
of October 1998
8
 Law of protection of personal data. 
Deliberation no. 333/20079 
Related to protection of personal data in clinical trials of medicinal 
products for human use. 
Decree-Law no. 102/2007, 
2nd of April 200710 
Establish the principles and guidelines of GCP as regards IP for human 
use, as well as the requirements for authorizing the manufacture or 
import of such products. 
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1.1. Clinical Trials in Portugal – Actual scenario 
 
The number of clinical trials in Europe is stagnating or even decreasing and Portugal has also followed this 
trend.11 According to the data available on INFARMED’s (National Authority of Health Medicines and 
Products) website, the number of submissions of clinical trials is gradually declining, as summarized in Table 
3. From the analysis of this table, in 2010, from the 107 clinical trials submitted to INFARMED, 105 were 
approved. Although, comparing this data with the data from the previous years, it is possible to verify that 
the number of clinical trials applications is decreasing.
12
 This year, 2011, until 6
th 
of May, only 19 clinical 
trials had been submitted to INFARMED.12 
Table 3. Clinical trials application submitted to INFARMED – annual statistics: number of clinical trials 
submitted, authorized, not authorized and average time for authorization.12 
Clinical Trial Application (CTA) 2005 
2
nd
 Half 
2006 2007 2008 2009 2010 2011 
1
st
 Half 
CTA Submitted 108 160 136 146 116 107 19 
CTA Authorized 26 147 131 138 116 105 27 
CTA Not Authorized 0 1 0 0 0 2 0 
Average time for authorization (days)  - - 45 43 42 42 45 
Adapted from INFARMED website. 
 
 
The decrease of clinical trial applications can be explained by the delay in the approval of new clinical trials 
by the regulatory authorities and by the administration boards of Portuguese hospitals, which, in some 
cases, take more than six months. On the other hand, the decrease of CTA could also be explained by the 
actual economic scenario that Portugal is experiencing, or even by all the bureaucracy involved. Thus, 
pharmaceutical industries prefer to choose countries where the submission/approval processes are faster.11 
The TRS facilitates the clinical research work and the existence of this logistic support department may 
determine that HIP is more often involved in new clinical studies. TRS ensures that, among other 
procedures, the HIP administration board approval is obtained in an acceptable period. 
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2. Host Institution 
HIP is a district hospital with more than thirty years of existence.13 It serves the population of Aveiro, 
Águeda, Albergaria-a-Velha, Ílhavo, Oliveira do Bairro, Murtosa, Vagos, Estarreja and Sever do Vouga. HIP 
works with Hospital Distrital Visconde de Salréu (Estarreja) and with Hospital Distrital de Águeda. HIP is also 
connected with Hospitais da Universidade de Coimbra, E.P.E. (HUC),14 the principal referral hospital for HIP. 
The mission of HIP is to provide healthcare to its patients, with efficiency and quality, within a framework of 
sustainable economic and financial development, promoting participation in pre- and post-graduate 
training, development of clinical research and constant improvement of management techniques.13 Timely 
responses to patients’ needs and technical and human quality are the goals of HIP in order to be considered 
a referral hospital and to be recognized as one of the best Portuguese hospitals.13 The HIP values are: ethic, 
quality, social responsibility, innovation and respect for the individual.13 
The hospital of Aveiro was founded in 1895, when the provider of the Santa Casa da Misericórdia, Viscount 
of Silva Melo, became interested in the construction of a new hospital, Hospital da Misericórdia de Aveiro.14 
The land was purchased in 1899 and in the 15th of October 1901 the construction of the new hospital 
began.14 In 1976, Hospital da Misericórdia de Aveiro became Hospital Distrital de Aveiro.14 In December 
2002, Hospital de Aveiro was included in the group of thirty-one hospitals that have been given the status of 
Anonymous Society (hospital S.A.).14 In 2005, it became an Enterprise Public Entity (hospital E.P.E.).14 
When the first clinical studies began in HIP, the TRS was not established. In this phase, all work was done by 
the investigators and their research teams. However, the number of proposed clinical studies increased and 
HIP felt the need to create the TRS. This service was created in the 12
th
 of January 2009 and its main 
objective is to provide support to the coordination and conduction of clinical studies in order to expedite 
the clinical research developed in HIP. 
The TRS operated under direct supervision of Prof. Doutor Francisco Pimentel, the former president of 
administration board of HIP. It is composed by two areas: (1) training and medical internship and (2) clinical 
research.  
The clinical research activities in TRS started with Dra. Maria Vale, the first professional who conducted and 
supervised these activities in HIP. The TRS facilities are equipped with desks, chairs, stationaries, 
telephones, printer, scanner and computers with access to Internet and Intranet. 
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TRS is linked to the general logistics support departments, one of the three functional areas of HIP. These 
functional areas are summarized in Table 4.
13
 
Table 4. Organization of functional areas of HIP.13 
 
Functional Area Departments / Areas 
Departments or units of 
healthcare provision 
Departments (functional units, if applicable) – psychiatry; anaesthesiology 
(pain unit); pathologic anatomy; cardiology (coronary intensive care unit); 
surgery; dermatology; stomatology; endocrinology (nutrition unit and diabetic 
foot unit); gastroenterology; imaging; immunoallergology; 
immunohaemotherapy; infectious diseases; rehabilitation and physical 
medicine; work medicine; intensive medicine; internal medicine; nephrology; 
neurology (stroke unit); gynaecology/obstetrics; ophthalmology; oncology; 
orthopaedic; otorhinolaryngology; pathology; paediatrics/neonatology; 
pulmonology; rheumatology; urgency/emergency; urology. 
Logistics support 
departments related to 
healthcare provision 
Pharmacy; procurement; customer management; sterilization, housekeeping 
management and social department. 
General logistics 
support departments 
Audits; TRS; information for management; image and communication; legal 
service; facilities and equipment; environmental management; human 
resources; financial department and informatics.  
 
Although TRS was created to give support to all departments of HIP, the main departments that requested 
support are: cardiology, oncology, endocrinology, rheumatology and infectious diseases departments. A 
brief characterization of these five departments is presented below. 
Cardiology 
The cardiology department is composed by a coronary intensive care unit (known as UCIC) with five beds, 
nurse ward with twelve beds, pantry, clinic secretariat and living room. The activity of this department is 
spread by ambulatory outpatient consultations (hypertension, ischemic heart disease and heart failure), 
UCIC, emergency and pacemaker implantation. It is possible to perform electrocardiograms, 
echocardiograms and ABPM (ambulatory blood pressure measurement) in this department. The staff is 
composed by ten cardiologists, one intern physician, seven technicians of cardiology and twenty-three 
nurses. 
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Oncology 
The oncology department is composed by the nurse ward, clinic secretariat, treatment room and living 
room. Medical specialists refer their patients to oncologic consultation. When necessary, agreements are 
established with other institutions to perform some specific exams (e.g. biopsies, computerized 
tomography). Two oncologists, three intern physicians and nine nurses compose the staff of the oncology 
department. 
Endocrinology 
The endocrinology department is composed by the nurse ward, clinic secretariat, day hospital, pantry and 
living room. The activity of this department is spread by endocrinology, diabetology, paediatric diabetology, 
nutrition and high diabetic obstetric risk consultations and day hospital. Two endocrinologists, one intern 
physician and ten nurses compose the staff of the endocrinology department. 
Rheumatology 
The rheumatology department is composed by the clinic secretariat, living room and consultation rooms. 
Among others, the activity of this department is spread by rheumatoid arthritis, ankylosing spondylitis, 
spondylarthritis and lupus erythematous consultations. The staff is composed by three rheumatologists, 
one intern physician and nine nurses. 
Infectious diseases 
The infectious diseases department is composed by the nursing work rooms, day hospital, clinic secretariat, 
treatment rooms, pantry and living room. The nurse ward has eighteen beds, of which, six are officially 
attributed to patients of this department. Two rooms are equipped with negative pressure system and fresh 
air. The activity of this department is spread by ambulatory outpatient consultations, day hospital and 
urgency. Samples for specific analytical tests are collected by nurses and are processed either by the HIP or 
by the HUC. In the last situation, the results are quickly sent by fax or are brought back by the driver who 
transports the samples, without subject confidentiality prejudice. The staff is composed by three specialists 
in infectious diseases, two intern physicians and sixteen nurses. 
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3. Curricular Training Objectives 
The main objectives of this training were: 
 To learn how to coordinate different clinical trials and observational studies in different medical 
specialties; 
 To apply GCP requirements, protocol specificities and the applicable laws and regulations required 
in clinical research; 
 To develop the personal, interpersonal, search and linguistic skills necessary for working in the 
clinical research area. 
 
In order to achieve the main objectives, the specific objectives of the curricular training were to: 
 
 Develop databases that gather clinical studies information and that improve their traceability; 
 Train on how to properly handle the clinical research concepts; 
 Search and organize relevant clinical data; 
 Assess the feasibility of clinical studies; 
 Verify and facilitate formal clinical studies approval; 
 Prepare pre-selection/selection and initiation visits; 
 Plan the execution of clinical studies; 
 Assist in subject recruitment; 
 Prepare study visits and coordinate study procedures; 
 Use the interactive voice/web response systems;  
 Collect accurate and verifiable data and learn how to properly register that data on case report 
forms; 
 Maintain stocks of study and lab materials; 
 Process, store and send study samples to central lab;  
 Assure study drug compliance (drug accountability); 
 Prepare the documents related to subjects’ reimbursements; 
 Communicate with sponsor, monitor and with the other elements of the research team and, if 
applicable with regulatory authorities; 
 Prepare monitoring visits and interact with monitors; 
 Coordinate study close out visits; 
 Safeguard the adherence to GCP, protocol and applicable laws and regulations; 
 Archive study documents and maintain study documents updated and organised; 
 Prepare study site payments. 
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Chapter 2: Generic Training 
The generic training typically refers to activities held in other departments, whilst the specific training 
occurred in the TRS. So, this chapter describes all activities performed in other departments of the host 
institution. However, as my curricular training only took place in the TRS, I will present a brief description of 
a training course that I attended in an external institution, as well as a summary of a review text that I was 
suggested to do. 
In October of 2010, I had the opportunity to participate in a training course in an external institution. The 
training course on “Clinical Research Training” was carried out in Faculdade de Medicina da Universidade de 
Coimbra (FMUC), on 29th and 30th of October 2010. This training course was organized by AIBILI (Association 
for Innovation and Biomedical Research on Light and Image) and it was sponsored by INFARMED and FMUC. 
The training was divided into six themes: introduction (clinical research concept and definition and 
classification of clinical trials and observational studies); ethical principles in clinical research; introduction 
to biostatistics (design of clinical trials and observational studies); good clinical practices (GCP-ICH 
guidelines; investigator, monitor and sponsor responsibilities; and the informed consent form); 
coordination and organization of a clinical trial in a study site; and quality (quality control and quality 
assurance; audits and inspections). 
Attending this training took a total of fifteen hours of duration. This was a very enriching activity because it 
allowed me to consolidate the concepts and to learn with the lecturers, known experts in clinical research. 
Additionally, I had the opportunity to participate in a literature search and subsequent organization of the 
information, in the format of a review text, related to the theme “quality of oncology clinical practice 
guidelines”. The requested task was to outline a review text to analyse if oncology clinical practice 
guidelines improve the quality of care received by oncologic patients. To prepare this review text, literature 
search was performed in MEDLINE and Cochrane Library databases, covering original articles and 
systematic reviews from 1990 to 2010. Only oncology guidelines were considered. The final version of the 
review text was send to HIP administration board for the final revision. 
Carrying out this task took me about two weeks. To perform it, it was very important to know the purpose 
of the review. Article selection was a fundamental step for the final review text success. The compilation of 
all data collected from the different selected articles was the most challenging task. 
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Chapter 3: Specific Training 
1. Flowchart: Clinical Trial Steps 
While implementing a clinical trial, there are three key phases related to the regulatory authorities: before, 
during and after the submission of a clinical trial to regulatory authorities. The flowchart (Figure 3) 
illustrates the process identifying the inputs, outputs, responsibilities and some important comments. The 
several steps (1 to 9) are explained below. 
Before the submission of a clinical trial to the regulatory authorities, sponsor should make a previous 
evaluation about some fundamental parameters that could influence the clinical trial success. According to 
the flowchart (Figure 3), the first step to be performed is the assessment of the study site feasibility to 
conduct and carry out the clinical study. In this stage, the confidentiality agreement and the feasibility 
questionnaire are completed (step 1). The confidentiality agreement is established between the sponsor 
and the investigator/site. This document guarantees the confidentiality of information for a specified period 
or until the publication of such information.15 The feasibility questionnaire intends to determine and 
document the viability of a clinical trial at the study site.
16
 This study assesses the available human and 
material resources, the recruitment potential and if the research team has experience in clinical research 
and in GCP training.16-17 According to the feasibility study, the selection of the study sites – selection visit 
begins (step 1). The Sponsor performs this visit and its main goal is to evaluate and select sites and 
investigators to conduct the trial.18 Although the selection visit can be performed by telephone, fax, e-mail 
or with questionnaires,
18
 preferably, this visit should be performed on site. Several topics should be 
discussed in this visit, such as: study protocol, study drug, regulatory aspects, necessary documentation, 
research team responsibilities, source documents, monitoring visits, equipment and facilities, recruitment, 
GCP principles and the possibility of a auditory and/or inspection. Also, human resources, competitive trials 
on the site, protocol and procedures that may require specific equipment should be discussed, as well as 
other departments involved (pharmacy, laboratory, etc.).
18
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Figure 3. Flowchart representing the main clinical trial steps, before, during and after submission to 
regulatory authorities. Abbreviations: INFARMED – National Authority of Health Medicines and Products; 
CNPD – National Committee for Data Protection; CEIC – Ethics Committee for Clinical Research; PI – 
principal investigator; IVRS/IWRS – interactive voice response system/interactive web response system; ID – 
identification; ICF – informed consent form; IP – investigational product; CRF – case report form. 
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The next step is the submission of the clinical trial to regulatory authorities (step 2). Before a clinical trial 
can be initiated, the regulatory authorities must approve it. In Portugal, these regulatory authorities are: 
INFARMED (National Authority of Health Medicines and Products); CNPD (National Committee for Data 
Protection); and CEIC (Ethics Committee for Clinical Research).
5
 The study approval by the site 
administration board is also required and is established by a Financial Agreement. This document is 
established between sponsor, study site and the PI,15 and it should describe and acknowledge 
responsibilities, terms of collaboration, requirements for payment and reimbursement, publication and 
intellectual property terms, indemnification and insurance, subject injury coverage, grounds for termination 
of contract and possibility of amending contract terms in the future.15 Direct and indirect costs are also 
documented in the financial agreement.
15
 Direct costs are the costs related to research team payments and 
the indirect costs are the costs spent with the use of complementary means of diagnosis and therapeutics, 
unintended hospitalizations and expenses and losses incurred by participants.5 Usually, the sponsor 
delegates these first presented steps on the monitors. 
After the approval by the regulatory authorities, the trial can now start. This process begins with the 
initiation visit (step 3). The main goal of this visit is to leave the site totally able to initialize the trial.18 In this 
visit, the monitor explains the research team’s responsibilities, study procedures, case report form (CRF), AE 
and SAE notification, study drug, clinical reports and source documents, ICF and biological samples 
collection.18 At the end of this visit, some important tasks should be fulfilled: delegate responsibilities and 
training the research team, provide all necessary material, explain all study procedures and obtain 
important documents like the curriculum vitæ (CV) of the different team members.18 All study 
documentation is archived on the Investigator Site File (ISF).18 
Investigators can now recruit participants to the trial. The recruitment period is a period during which the 
investigator is attempting to identify and enrol participants who meet the eligibility criteria.3 The selected 
subjects must perform the screening visit and have to sign and date the ICF, before any trial procedure is 
performed. The identified potential participants are screened in order to ensure that they meet all eligibility 
criteria and, consequently, they can be randomized to the trial (if applicable) (step 4). The eligibility criteria 
are summary criteria that determine if a person may or may not be selected to participate in a clinical 
study.
3
 These comprise the inclusion and the exclusion criteria.
3
 Randomization is a method by which 
participants are randomly assigned to a treatment arm (for randomized clinical trials).
3
 Randomization is 
made using the interactive voice response system or interactive web response system (IVRS or IWRS). 
Preferably, the investigator should perform this task; however the study coordinator can assume this 
responsibility, always under the investigator supervision. During the randomization call, an assignment of a 
subject identification number will be issued and the subject will be assigned to a study treatment arm. 
Usually, this is the first time that patients are assigned to the study drug. Specific study drug kit numbers, 
assigned by the IWRS or IVRS, identifies the study drug assigned to a specific subject. In non-randomized 
16 
 
clinical trials, the study drug is dispensed to subjects without using the IVRS/IWRS. A clinical trial in which 
the investigator and the subject know which treatment is being administered to the subject is called an 
“open-label study”.3 If one or more parties involved in the clinical trial are unaware of the treatment 
assignments, the trial is called “blinded”. A study in which one part, either the investigator or the subject, is 
unaware of the treatment assignments is called a “single-blind study”.3 A clinical trial in which both 
investigator and subject are unaware of the treatment assignments is called a “double-blind study”.3 There 
are also clinical trials where the investigator, the subject and the data analyst are unaware of the treatment 
assignments. In this situation, these clinical trials are called “triple-blind studies”.
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There are some clinical trials in which a run-in period is established. This period is established in some 
protocols for several reasons, depending on the purpose of the trial itself (e.g. adherence to study drug, 
confirmation of eligibility criteria). Then, the clinical phase of the trial begins – the treatment study visits 
(step 5). Treatment study visits are performed according to periods established in the study protocol and 
vary from protocol to protocol. A series of clinical tests and procedures will be performed at specified 
intervals throughout the study.18 For each visit, there are study procedures that must be strictly performed. 
Some study procedures examples are: obtain the ICF; demographics and medical/surgical history (e.g. age, 
birth date, race, documentation of any clinically significant medical condition, tobacco and alcohol use); 
physical examination (e.g. weight, height); vital signs (e.g. blood pressure, heart rate, body temperature); 
perform exams (e.g. electrocardiogram, echocardiogram, computed tomography, X-ray); clinical laboratory 
tests (e.g. chemistry, coagulation, haematology, urinalysis); pregnancy test; concomitant medication; AE 
and/or SAE; quality of life assessments; dispensation of study drug.18 
After the investigator and his research team meet all study procedures for a particular visit, they can, 
through IVRS or IWRS, assign the subsequent study drug kit numbers to a subject. Generally, clinical studies 
require the dispensed study drug kit numbers to be confirmed in the IVRS or IWRS to guarantee that the 
right kits are dispensed to the right subject. For each visit, the study pharmacist should verify the returned 
study drug, which is designated as “drug accountability”. This task consists in verifying the number of 
returned pills, comparing it to the total number of dispensed pills (in case of oral pills). Based on 
dispensed/returned study drug, study pharmacists perform study drug accountability and adherence 
calculation. If non-adherence is detected, they should communicate with the investigator. All study drugs at 
the study site should be adequately stored and the temperature and moisture has to be monitored at the 
pharmacy.20 
At the end of the treatment clinical phase or in case of early discontinuation of a subject, the end of 
treatment visits and subsequent follow-up visits are performed (step 6). In the end of a treatment visit, 
patients stop taking the study drug and depending on the therapeutic area, they may be switched to a 
commercial medication or continuing taking the study drug (outside the context of the trial) until it is 
available on the market, in case there are no alternative therapeutics available and the patient is clearly 
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benefiting from the study drug.5 Depending on the trials, at this visit, some procedures may also be 
performed in order to assess patient progression during the trial like cognitive tests and health and life 
questionnaires. All patients are followed after the last dose of study drug is administered. The purpose of 
these follow-up visits is to assess the subjects’ clinical status after study drug discontinuation. At the end of 
the clinical treatment phase or in case of early discontinuation of a subject, an end of treatment visit is also 
performed.  
All visits must be introduced in the CRF. These forms are used to transmit the information collected during 
the study to the sponsor and to the regulatory authorities, if applicable.
18
 The investigator records all 
required data in the subject files and these subject files serve as source documents (original documents, 
data, and records2) for the trial. Source documents have to be available at monitoring visits and also in case 
of audits and/or inspections. The investigator is required to prepare and maintain adequate case histories 
designated to record all observations and other data pertinent to the trial. All data reported in the CRF must 
be derived from source documents and must be consistent with the source documents.18 In the monitoring 
visits, the monitor confirms all the information entered in the CRF with the source documents: if the patient 
had all the inclusion and none of the exclusion criteria; if all the procedures were performed for each visit; 
all the concomitant medications and AE recorded; the study drug dispensed to the patient was the one 
assigned by the IVRS/IWRS; etc. The investigator should ensure that the data is timely reported, being both 
complete and accurate.16 
The close out of the study (step 7), also known as closure visit, is performed when: (1) the study site meets 
the study protocol; (2) the sponsor decides to finish the trial; or (3) by the request of investigator, 
CEIC/Local Ethical Committee or other regulatory authority. Among other tasks, in this visit, the monitor 
should: verify all open issues that are present in the last monitoring report; verify the list of equipment to 
be returned from site; ensure the final reconciliation of study drug; ensure the final reconciliation of all 
documentation; confirm that all CRF are complete and with no open queries. The investigator is also 
reminded about the need to archive all study related documentation during a minimum period defined by 
the sponsor.16 
When a clinical trial ends, this conclusion should be notified to INFARMED, CEIC, CNPD and to the 
administration board of the site within ninety days.
5
 However, if the end of the trial is anticipated, the 
notification to regulatory authorities must be made within fifteen days.
5
 Trial data are then analysed by the 
sponsor and the results must be published (steps 8 and 9). 
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The three key phases related to study submission in clinical trials are also applicable to observational 
studies. In order to perform these studies, the Local Ethical Committee’s (ethical committees from study 
sites) positive opinion is required, along with a positive opinion from the CNPD. When the CNPD and the 
Local Ethical Committee approve the study, the submission documentation is conducted to the study site 
administration board to obtain approval for the conduction of the study in their facilities. The establishment 
of a Financial Agreement between sponsor, study site and PI determines this approval. 
After the approval by regulatory authorities, the study can be initialized and the investigator can now 
recruit participants to the study. The subjects selected to perform the screening visit must also sign and 
date the ICF, just like in a clinical trial.5 There are also clinical studies that do not require the obtainment of 
the ICF (e.g. retrospective studies). At the end of the study, data is also analysed and the results are 
communicated.  
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2. Work performed as Clinical Study Coordinator 
According to the Association of Clinical Research Professionals, a Clinical Research Coordinator or Clinical 
Study Coordinator “works at a clinical research site under the immediate direction of a PI, whose research 
activities are conducted under GCP and ICH guidelines”.21 According to the same association, a clinical 
research site is “the location(s) where trial-related activities are actually conducted”.2 
Since my curricular training involved the collaboration and contact with health professionals from some 
medical departments from HIP, my supervisor introduced me in the different departments as a trainee. 
The next two topics present the activities performed during my curricular training: databases creation (2.1.) 
and followed clinical trials and observational studies (2.2.). 
 
2.1. Databases Creation 
At the beginning of my curricular training, one of the first activities that I performed was the creation of 
three databases: one for clinical trials, other for observational studies and the last one for clinical research 
projects. These databases were created to organize a repository of clinical studies information with the aim 
of optimizing the studies archive, as well as making the study search faster. 
The databases for clinical trials and observational studies presented information like: study title, study 
phase (in case of an interventional study), sponsor, approval date in HIP, start date of the study in HIP, PI, 
sub-investigators, study pharmacists and nurses, the actual state of the study and the department(s) where 
the clinical study is performed. All studies/trials were entered in the respective database and they were 
associated with a study code, in the format XX–XXXX–X (this code corresponds to department code – year – 
study acronym). When a new clinical study was approved in HIP or when a clinical study was finished, 
databases were updated. 
The database for clinical research projects presented information like project title, investigator, supervisor, 
co supervisor, approval date in HIP and the department(s) where the research project is performed. Like the 
clinical trials/observation studies databases, all clinical research projects were also associated with a code, 
in the format XX–XX–XXXX (this code corresponds to department code – study number – year). When a new 
project was approved in HIP, this database was updated and the submission documents were properly 
labelled and archived in the appropriate folders. 
Carrying out this task took me about three to four weeks. This first activity was a very important task and 
very well positioned in time because it allowed me to be aware of the number of clinical studies that 
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existed in HIP, helped me to know the investigators and research teams involved in clinical research, as well 
as to learn about the different therapeutic areas studied, study phases and main purposes. 
 
2.2. Followed Clinical Trials and Observational Studies 
In HIP, there were several ongoing clinical trials and observational studies that required additional effort 
and availability from the research team. There were many medical departments that conducted clinical 
trials and/or observational studies. However, just some of them ordered for the involvement of TRS. The 
main clinical departments where I have performed as a clinical study coordinator were, as previously 
stated: cardiology, oncology, infectious diseases, endocrinology and rheumatology. In these five 
departments, I had the opportunity to follow twenty clinical trials and four observational studies, 
distributed as listed below: 
 
 Cardiology – Seven clinical trials; 
 Oncology – Seven clinical trials and four observational studies; 
 Infectious diseases – Two clinical trials; 
 Endocrinology – One clinical trial; 
 Rheumatology – Three clinical trials. 
First, I will provide a description of all tasks performed as a clinical study coordinator, which are identical for 
all studies and, finally, I will present a more detailed description of the activities performed in each 
particular study (if applicable).  
Performing clinical studies coordination in HIP occurred during all curricular training, in a period of ten 
months. The main activity performed as clinical study coordinator was the coordination and organization of 
the approval process and conduction of clinical trials and observational studies. Some important procedures 
done for all clinical studies were to: 
 Assess clinical study feasibility; 
 Verify and facilitate formal clinical study approval; 
 Prepare pre-selection/selection and initiation visits; 
 Plan the execution of clinical study; 
 Assist in subject recruitment; 
 Prepare study visits and coordinate study procedures; 
 Access to IVRS or IWRS;  
 Collect accurate and verifiable data and register all required data in CRF; 
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 Maintain stocks of study and lab materials; 
 Process, store and send study samples to central lab;  
 Assure study drug compliance (drug accountability); 
 Prepare the documents related to subjects’ reimbursements; 
 Communicate with sponsor, monitor and with the other elements of the research team and, if 
applicable with regulatory authorities; 
 Prepare monitoring visits and interact with monitors; 
 Coordinate study close out visits; 
 Safeguard the adherence to GCP principles, protocol and applicable laws and regulations; 
 Archive study documents and maintain study documents updated and organised; 
 Prepare study site payments. 
 
All these activities are described below, showing the tasks that I performed during my curricular training. 
Assessment of clinical studies feasibility 
When sponsors are recruiting study sites to participate in their clinical studies, they send out interest 
feasibility questionnaires to potential sites. Usually, this first contact with the study sites is done with 
potential investigators, but it can also be performed with study coordinators, if they exist at the study sites. 
When a study site receives a feasibility questionnaire, it is usually accompanied by a brief protocol synopsis.  
During the curricular training period, I had the opportunity to verify, at least, sixteen study feasibility 
assessments. Although the questionnaires were related to different studies from different sponsors, I 
noticed that the required information was very similar: logistical conditions, human resources/staff 
availability, subject recruitment, research team experience and training. My specific functions in this 
feasibility evaluation process were to: obtain the confidential agreement; ensure completion of all required 
fields/questions; and establish a good communication with the investigator(s) and with the monitor in order 
to complete; and to return the feasibility questionnaire in two to three days. 
Verification and facilitation of formal clinical study approval 
When a new study was submitted to HIP, before sending the submission documents to the administration 
board, I reviewed the submission file in order to verify if the necessary documents were present and to 
evaluate if the financial agreement was established according to the HIP rules. A checklist of all of the 
required documents was filled out. According to the HIP internal requisites, the submission file must 
include: study protocol; solicitation letter; ICF copy; investigator CV; authorization of the head of the 
department where the clinical study will be performed; positive opinion of the CEIC (in case of an 
interventional study) or of the Local Ethical Committee (in case of an observational study); positive opinion 
of CNPD; positive opinion of the INFARMED (in case of an interventional study); positive opinion of the HIP 
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administration board; financial agreement signed and dated by the sponsor and the PI; and insurance 
certificate (in case of an interventional study). If all documents were present, I would send the submission 
file to the administration board for the final approval. The establishment of the financial agreement 
determines this approval (three originals of the financial agreement were signed and dated by the sponsor, 
the PI and by the administration board of HIP). After this process was completed, I would send two originals 
of the financial agreement to the monitor. 
In the submission process, my specific functions were to: review the submission file; propose amendments, 
corrections and/or improvements to the submission documents; establish a good communication with all 
involved parties in order to obtain the signed and dated financial agreements; produce and send the 
approval craft to the monitor; and send two originals of the financial agreement to the monitor in no more 
than two to three weeks. During the curricular training period, I had the opportunity to work with, at least, 
twelve submissions to the administration board of HIP. 
Preparation of pre-selection/selection and initiation visits 
The usual procedure for pre-selection/selection visits implies that the monitor comes to the study site to 
perform this visit. When the pre-selection/selection visit was not an in-person visit, my roles were to: 
collect the necessary documents used in the submission process (e.g. investigators’ CV) and send them to 
the monitor; facilitate the communication between the PI and the monitor; and clarify the monitor’s 
questions. Additionally, I had to ensure that the research team reserved the planned date for the initiation 
visit. I only had the opportunity to witness one selection visit. 
Initiation visits were always performed in-person. In these visits, I received adequate training on the 
protocol along with the research team (e.g. study objectives, ICF, AE/SAE reporting, GCP principles, study 
drug, CRF); some important documents were collected (e.g. subject pre-screening logs, delegation log); and 
the recruitment was discussed. In most cases, some documents were still missing, so I had to collect them 
and send them to the monitor (e.g. research team’s CV, delegation log, financial disclosure forms). During 
the curricular training period, I had the opportunity to follow, at least, ten initiation visits. 
Planning of clinical study execution 
The study planning should start when the sponsor approves the participation of HIP in the study. At this 
point, the PI, the research team and I talked about issues related to the next steps of the clinical study, 
including the assessment of the realistic way to include patients. Additionally, if the study visit scripts to the 
different visits, study drug dispensation forms, nurse forms, and visit planners were not provided by the 
sponsor and if the sponsor allowed me to do/use them, I prepared and adjusted them. 
Whenever a new clinical study started, planning its execution was fundamental. From there, at least once a 
week, it was necessary to review the performed work in order to check if all planned goals were achieved. 
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The teamwork and the cooperation with all health professionals involved in the different studies are 
essential to correctly plan the work. 
Assistance in subject recruitment 
Whenever a new clinical study started in HIP, the PI, the sub-investigators and I, tried to select possible 
subjects to screen with the objective of enrolling them in the study. After defining a subject pre-screening 
list, we carefully assessed the eligibility criteria in order to certify that the selected potential participants 
met all the inclusion criteria and none of the exclusion criteria. This was a fundamental task to ensure that 
the research team reached the number of proposed subjects – recruitment objective (the proposed goal 
agreed in the financial agreement to our study site). To select potential participants in retrospective studies, 
I needed to carefully analyse Medical Support System (SAM) application and/or clinical patient files from 
patients who were medicated with the therapeutic indication in study. In this process, I had also to check if 
all eligibility criteria were met. In this phase, before enrolling or randomizing a new subject, the eligibility 
criteria were also verified or, if applicable, re-verified. 
In cooperation with the PI and/or investigators, during the recruitment process, my functions were to: 
identify and select potential subjects; define a subject pre-screening list and, later, a subject enrolment list; 
analyse the eligibility criteria; and enrol and/or randomize subjects to the study. 
Compliance with all eligibility criteria is essential and it should be respected by all investigators. These 
criteria are established based on safety parameters that should be considered when including subjects to 
ensure their safety and well-being.3 
Preparation of study visits and coordination of study procedures 
After the enrolment of a subject, I had to schedule the next study visits according to study protocol. My 
main function was to ensure that all required study procedures for each visit were completed. Thus, the 
preparation prior to the study visits was essential. To prepare a study visit, I resorted to study protocol. 
Additionally, I prepared all necessary forms (considered source documents) to register all clinical data, such 
as: study drug dispensation form, nurse form, study visit script, health questionnaires required by protocol 
(e.g. EQ-5D, Euro Quality of Life-5 Dimension Questionnaire, a standardized instrument for use as a 
measure of health outcome) and other specific forms required (e.g. physical examination forms). In certain 
visits, it was also necessary to prepare study kit(s) for samples collection: blood and/or urine. Kits were 
provided by the sponsor/central lab and were already prepared for a particular visit. However, I had to 
identify the collection tubes, slides or other collection materials with the subject details. 
One important visit that should be carefully prepared is the randomization visit. This visit, when subjects are 
assigned to a study treatment arm, coincided mainly with the first study visit. However, some study 
protocols defined a run-in period. In these situations, the randomization visit was performed after the run-
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in period completion. To randomize a subject, I had to access to IVRS or IWRS and introduce some required 
subject details. The IVRS/IWRS allocated the subject to a study treatment arm and also gave the subject 
identification number (also known as subject ID/subject number). Usually, the assignment of study drug 
happens only after subject randomization. 
When preparing a study visit, I ensured that the subjects would attend those appointments. Thus, some 
days before the study visit, I contacted the subjects to remind them of the scheduled visits. Contacts were 
also made to schedule some complementary exams. 
Three to four study visits per week were appointed and carried out. All visits were prepared in advance to 
ensure that all protocol required procedures and measurements were met. 
To maintain the research team informed about the study visit appointments, “Study Visit Planners” were 
prepared and placed in the physicians’ workroom. These visit planners were updated monthly. 
Accessing to IVRS or IWRS 
To expedite some clinical research activities, two systems are used: IVRS and IWRS. The IVRS is a phone 
system application that prompts callers with recorded messages, menus and options and processes voice 
input and/or touch-phone keypad selections from these menus. The IVRS script responds to this input by 
providing appropriate information in the form of voice answer.22 The IWRS is the web-based equivalent of 
IVRS, where instead of the telephone, a secure webpage is used as the interface with a central computer, 
enabling the user to select menu options and to enter and receive data and instructions.23 Often, these 
systems are combined with fax/e-mail service and perhaps with other media. This allows users to receive 
evidence of the performed activities. These two systems are highly accepted by users as they provide 
results in real time. They are used to randomize subjects, screen subjects, assign study drug, withdraw 
subjects, confirm attributed study drug kit numbers, suspend or restart study drug, among others. 
All platforms of IVRS/IWRS require a login at every access, from which I can normally make the transactions. 
At the beginning of a new clinical trial, I received training on how to properly access and use the study 
IVRS/IWRS by the sponsor, who also provided me with the first access codes. For the platform of each 
study, I had a different username and password. 
I accessed the IVRS or IWRS platforms to: randomize subjects to a study; obtain the subject identification 
number; assign the subsequent study drug kit numbers; discontinue/interrupt/re-start study drug; confirm 
study visit numbers and/or study drug kit numbers; and to perform the unblinding procedure. Some 
systems were prepared with more option menus, specific for the different studies. 
In rare cases, the unblinding of the study drug is required. This may occur as a result of an adverse event 
where it is necessary to know the study treatment arm that was being administered to the subject in order 
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to determine how to treat the event. I had the opportunity to perform one unblinding (or code break) 
procedure. Unblinding is the process by which the randomization code is broken so that the investigator 
and the research team become aware of the treatment assignment for a specific subject participating in a 
clinical trial.
2
 In most cases, the person permitted to perform the unblinding procedure is restricted to the 
PI. However, I was consented by the PI to perform this task. Thus, it was necessary to activate the code 
break envelope provided by sponsor. These new access codes allow access to a new menu option in the 
IVRS/IWRS: unblinding. By accessing this new menu option, it was only necessary to provide patient details 
and the system immediately returned the treatment that the subject was receiving. 
During the curricular training period, I had the opportunity to work with seven different IWRS platforms and 
with three different IVRS platforms. 
Collection of accurate and verifiable data and registration of all required data in CRF 
According to ICH E 6 Guideline for Good Clinical Practice, a CRF is “a printed, optical or electronic document 
designed to record all of the protocol required information to be reported to the sponsor on each trial 
subject”.2 A CRF is a data collection tool used to support investigators and coordinators in capturing all 
protocol-required information. The sponsor designs the contents of the forms and distributes them in paper 
or in electronic format to all study sites where the clinical study is being conducted.
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 CRF should be built so 
that they: gather accurate information that answers study questions and are consistent with study protocol; 
organize and label forms and fields so that data entry is intuitive; and avoid duplication of data.25 
The research team must ensure that data is entered accurately and its verification is possible at any time of 
the study. The CRF should be completed by authorized people, clearly and accurately. It must not be 
strikethrough and all forms and fields have to be completed. Any change or correction in the CRF (in case of 
paper formats) should be dated and validated by signature and should not hide the original data. 
For all electronic CRF, I had a different username and password. Each time I accessed these systems I was 
prompted to enter my login information. From there, I could make the transactions. At the beginning of a 
new clinical study, I received training on how to properly access and use the study CRF. 
All required data was entered in the CRF in no more than five working days after each study visit. When 
some data was missing, I scheduled an appointment with the investigator that performed the incomplete 
visits in order to get this information. 
During the data entry process, some automatic queries can be generated. Queries are related with 
questionable information. This means that the entered information is not valid or complete or that some 
data is missing. The data managers and monitors can also generate queries. These queries are used to 
request more information or to clarify the information provided. Each query must be resolved by the 
investigator or by the study coordinator. Then, queries are re-assessed by the sponsor. If the query is still 
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not clarified, a new query is generated and it will only be solved when the data manager/monitor is 
clarified. I tried to clean all queries in two to three days. A prompt response by the research site can be 
used to evaluate its performance. 
I had the opportunity to work with both formats of CRF: six different electronic platforms and two CRF in 
paper format. 
Maintenance of stocks of study and lab materials 
All clinical trials or observational studies had specific study materials. These materials were composed by:  
 Laboratory materials – kits for collection of samples, lab requisition forms and carton shipment 
boxes for sending samples at room temperature or in dry ice, specimens transport bags, absorbent 
tube shuttles and waybills. 
 Study materials – study visit scripts, study forms, study drug dispensing forms, some specific 
questionnaires, SAE forms and other specific documentation/forms. 
To avoid missing study material, I filled a reorder form to reorder supplies to HIP. This reorder form was 
faxed to a dedicated fax provided by the sponsor/central lab. The management of stocks is very important 
to ensure that, throughout the study, all necessary materials are accessible in the study site. 
Processing, storage and sending study samples to the central lab 
During my curricular training, I had the opportunity to handle three different types of study samples (or 
specimens): blood, urine and histological samples (tumour cells). Sample collection for research protocols 
requires specific attention to the proper timing, collection, labelling, processing, storage, and shipping. 
The first step to be performed was the preparation of study kits. Normally, clinical laboratory kits were used 
to collect study samples. Each kit was manufactured for a specific visit and was labelled with sponsor name, 
protocol number, study visit, and expiration date. When preparing lab kits, it was necessary to label all 
collection tubes. To properly label the tubes I should: fill out the required information on the requisition 
label; label the tubes at the time of sample collection and confirm that subject identification and other 
required information was correct; place the label in a vertical position and never wrap the label around the 
tube horizontally; do not adhere the label on the cap of the tube and do not cover any written information 
with the label. Some sponsors provided study kits already labelled. In this situation I just needed to properly 
fill out the required information. 
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The second step of this process was the preparation of study samples. After collection of samples, according 
to the study lab manual, it was necessary to prepare them for dispatch: 
 Blood samples – After collection of blood samples I should: completely and gently invert tubes; 
allow the blood to clot; centrifuge tubes using a defined amount of revolutions per minute and 
during few minutes; identify the transfer tube with the appropriate labels; transfer plasma, using a 
disposable pipette; avoid transferring any red blood cells; re-centrifuge if necessary; discard the 
collection tubes after transferring the plasma; secure caps; and store and send to central lab. Some 
collection tubes were sent without centrifuge. In these situations, I just needed to completely and 
gently invert tubes and store and send to central lab. These procedures can vary depending on 
protocol requirements. 
 Urine samples – When required per protocol, in certain study visits, subjects were provided with a 
urine vial. To properly collect urine sample subjects must be instructed that they must discard the 
first morning urine. Also using a pipette, a portion of urine was transferred to the transfer tube. 
These transfer tubes were also properly labelled. These procedures can also vary depending on 
protocol requirements. 
 Histological samples – In this situation, sample preparation was made by a clinicopathological 
technician. Concerning this type of samples, I just had to send them to central lab in order to be 
analysed.  
When handling and preparing samples, appropriate safety measurements should be taken, including the 
use of adequate protective equipment. 
The final step was the preparation of samples to send to the central lab. Samples were shipped at room 
temperature or they were stored in an upright position at -20oC on site and shipped later on dry ice (frozen 
shipment). A lab requisition form accompanied all study samples. The minimal required information that 
should be included in the lab requisition is: 
 Accession number or requisition number (this number associates the requisition to their respective 
labels); 
 Subject identification number and birth date; 
  Collection details; 
 Applicable study visit. 
Some lab requisitions presented the instructions on how to process lab samples. If it was not presented in 
the lab requisition, these instructions were presented in lab manual provided by the sponsor/central lab. 
When samples were prepared and all requisition form fields were carefully filled, I had to prepare the 
shipment. A shipment involves two steps: preparing the shipment box and arranging a pick up. To prepare 
the shipment box, I had to place the labelled tubes into the absorbent tube shuttles and place it inside the 
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specimen transport bag. If samples were shipped at room temperature, I placed the specimen transport bag 
in the carton shipment box with the respective requisition form. If samples were shipped in dry ice, the 
procedure is the same but I had to use a carton shipment box lined with foam.  Then, I had to fill the box 
with dry ice. Dry ice must be manipulated with special gloves and it should not be stored in a confined 
space. Dry ice handling has to be made according to International Air Transport Association rules. For all 
frozen shipments, I had to order dry ice by sending a specific form to the central lab. Finally, I had to 
arrange a pick up. To complete this task, I had to call to a carrier customer service and schedule a pick up 
day and time. Each individual shipment was combined under a single waybill. It helped to ensure timely, 
accurate and secure delivery. At least, a waybill should include: 
 Payer account name; 
 Person contact name; 
 Sender reference number, name and address; 
 Receiver name and address; 
 Shipment details; 
 Full description of contents. 
A carrier collected our samples and took them to the central lab. Lab results are later available by fax or e-
mail. 
Assuring study drug compliance (drug accountability) 
Study site should document study drug receipt, study drug dispensing and return of study drug (used and 
unused study drug kits). This is a study pharmacist function. However, I also performed such records to 
ensure that everything was adequately documented (ensure the adequate flow of study drug in and study 
drug out). 
When the study drug is received at the study site, it is important to inspect the shipment in its entirety and 
the proper study drug receipt records should be filled. Study drug should always be stored in a secure 
location and its storage conditions should be closely monitored. Temperature logs should be maintained in 
the storage area to ensure that the product remains viable. When dispensing study drug to a subject, I filled 
out the study drug dispensation form, recording the date, subject number, study drug kit numbers 
assigned/dispensed and the amount dispensed. When a subject returned the study drug, the amount of 
used and unused study drug were also documented, as well as any study interruption, inadvertent loss or 
destruction. 
Counting the used and unused study drug was a very important task in order to evaluate the subject study 
drug compliance; this is, to know immediately if subjects were properly taking the study drug. Drug 
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compliance is usually assessed in percentage and, whenever bad study drug compliance is detected, the PI 
and monitor should be informed. 
Preparation of the documents related to subject payments 
According to Law nº 46/2004, subjects included in a clinical trial are not granted with any incentives or 
financial inducements, but the reimbursement of the expenses and the compensation of damages incurred 
from the participation in the study are allowed.
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The expenses that were accepted by sponsors were: travel costs to and from study site; meal expenses 
incurred during the days of study visits, if the presence was required; and compensation for hours/days lost 
from work to attend the study appointments. All expenses must be accompanied with the respective 
invoice. Compensation for hours/days lost of work was only refunded if the subject presented a declaration 
of the employer that demonstrates the labour absence of subject during the study visit periods. All invoices 
were collected, verified and identified with subject number; then, they were forwarded to sponsor. Some 
specific documents were also filled to accompany the invoices in order to identify the subject and to 
explain/characterize the invoices. 
In our study site, we had the need to arrange a taxi service to make the transportation of some patients. In 
these situations, I had to collect the taxi invoices, send them to sponsor and, later, perform the payments. 
Two clinical trials required me to arrange a taxi service. 
Notification of adverse events and serious adverse events 
According to guideline ICH Topic E 6, an AE is “any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment”.2 AE can be symptoms (e.g. nausea, chest pain), signs (e.g. tachycardia, 
enlarged liver) or an abnormal result of an intervention (e.g. laboratory finding, electrocardiogram finding). 
An AE can also be an undesirable medical condition occurring at any time, including the run-in period, even 
if no IP had been administrated.2 
Prior to enrolment, the PI and I recorded each subject’s medical condition(s) – subject medical history. 
During the study, the PI and I continued alert to any changes in the clinical condition(s) and the occurrence 
of AE. The AE were collected from the time that ICF was signed, throughout the treatment period and until 
study completion (including follow-up period, when it is required per protocol). All AE were reported in 
patient files and in the CRF. 
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SAE collection also began after the subject had signed the ICF and it should be reported to sponsor within 
twenty-four hours, starting at the time that the research team is aware of the SAE. Also according to 
guideline ICH Topic E 6, a SAE is any clinical event that fulfils at least one of the following criteria: is fatal 
(results in death); requires initial or prolonged inpatient hospitalization; is life-threatening (i.e., increases 
the risk of death at any time of the event); results in persistent or significant disability/incapacity; is a 
congenital anomaly/birth defect; and is considered clinically significant by the investigator.2 After the ICF 
was signed, all SAE should be reported immediately to sponsor, in patient files and in the CRF. 
Any AE/SAE that was unresolved at the patient’s last AE/SAE assessment in the study was followed up in 
order to “control” it. The typically required information that I had to collect and then register in CRF was: 
event designation, start date, end date (if applicable), severity, causality, outcome, action taken with 
subject (e.g. concomitant medication) and with study drug (e.g. interruption, discontinuation), and if it was 
a SAE. If it was a SAE, the typically required information was: event designation, start date, end date (if 
applicable), severity, causality, outcome, action taken with subject and with study drug, serious criteria that 
categorized the event as serious, significant clinical tests, diagnostic procedures and lab parameters and a 
descriptive narrative of the event. In each new study visit, I prepared an ongoing AE/SAE list to discuss with 
investigator/subject. When the investigator and I followed the events, it was very important to provide the 
final outcome: completely recovered, recovered with sequelae, not recovered (i.e., ongoing), condition 
improving, or death. 
The intensity (i.e., severity) of an AE was graded using the Common Terminology Criteria for Adverse Events 
(CTCAE), version 3.0 and version 4.0.26 Intensity of AE that were not included in CTCAE criteria were 
assessed based on the investigator’s clinical judgment, using the following categories:
26-27
 
 Grade 1 (mild) – Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated; and no disruption of normal daily activity; 
 Grade 2 (moderate) – Moderate; minimal, local or non-invasive intervention indicated; discomfort 
sufficient to reduce or affect daily activity; 
 Grade 3 (severe) – Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling events that caused inability to 
work or perform normal daily activity; 
 Grade 4 – Life-threatening consequences; urgent intervention indicated; 
 Grade 5 – Death related to AE. 
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The causality relationship of study drug to the AE was assessed and categorized as below:27 
 Not related – it does not follow a reasonable temporal sequence with study drug administration; 
 Unlikely – reasonable temporal association with drug administration, but is more likely to have 
another cause which can explain the occurrence of the event; 
 Possibly related – reasonable temporal association with study drug administration, but the event 
could also be explained by another cause; 
 Probably related – reasonable temporal association with study drug administration and the event 
is more likely explained by the use of study drug than any other cause; 
 Definitely related – reasonable temporal association with study drug administration and there is no 
other cause that can explain the occurrence of the event. 
All AE/SAE that were related to study drug were designated as adverse reactions. When assessing the 
causality of the AE/SAE, alternative causes, such as subject medical history, underlying diseases, 
concomitant therapy, or other risk factors must be considered. Reporting possible adverse reactions is a 
very important task because it will help to identify AE that might be truly associated with study drug. 
The notification of AE occurred in almost all clinical studies. The most common AE, per department, were: 
 Cardiology – Anxiety, depression, hyperkalaemia, bleeding events, dizziness, and renal failure; 
 Oncology – Paresthesias, asthenia, thrombocytopenia, anaemia, anorexia, dizziness, mucositis, 
alopecia, anxiety and depression; 
 Infectious diseases – Anorexia, dizziness, anxiety, photosensibility reactions and rash; 
In the endocrinology department only one AE was reported: dizziness. In the rheumatology department no 
AE were reported because, at the end of my curricular training, subject enrolment process had not yet been 
initiated. In respect to the notification of SAE, it occurred in eight studies, mainly caused by unplanned 
hospitalizations. 
Communication with sponsor, monitor and with the other elements of the research team and, if 
applicable, with regulatory authorities 
During my training, I had the opportunity to talk with three people who came to HIP on behalf of the 
sponsor. In the first case, the meeting was scheduled to present a new clinical study; the second situation 
was to congratulate the research team for the good performance; and the third occasion was to discuss 
possible recruitment strategies. The physical presence of a sponsor representative is not frequent. Monitors 
were the people who established the communication between research teams and sponsor.  
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The main channels to communicate with the monitor were telephone and e-mail. The use of letters and 
faxes were not so common, but they were also a valid alternative. 
Whenever there was a question related to a clinical study, I contacted the monitor in order to help me to 
overcome/resolve the situation. Other types of communication included: re-order study material/lab 
material; request dry ice; report SAE; inform monitor of the study evolution (study status); receive/send 
study documents; receive and send responses/clarification of queries in paper format; send documentation 
related to subject payments; contact with other hospitals (e.g. subject hospitalizations/emergencies); 
contact with taxi services; contact with financial departments; contact with subjects and with other 
elements of the research team; collect study documents; prepare study visits, monitoring visits and, if 
applicable, audits; among others. 
When a trial was closed, I had to send a notification letter to CEIC and other to the administration board of 
HIP in order to notify the clinical study completion to these entities. I perform this task once during my 
curricular training. 
Preparation of monitoring visits 
An important function that I performed for all studies from all departments was the preparation and follow-
up of monitoring visits. The focus of these visits is to evaluate the way that the clinical study is being 
conducted and to perform source data verification (SDV) to ensure that all data collected were reliable and 
to ensure that reconstruction and evaluation of the study was possible. SDV is an evaluation of the 
conformity of the data presented in CRF with source documents.2 
To prepare a monitoring visit or even during a monitoring visit, I had to: 
 Identify a quiet place for the monitor to work; 
 Enter all available and required data in subjects’ CRF and resolve all open queries; 
 If applicable, confirm that all SAE forms were submitted to sponsor and are available for review; 
  Give monitor access to the ISF, patient files and patients clinical records (discharge notes, 
emergency records, concomitant drug prescriptions, among others); 
 Organize, update and archive all source documents in subject files; 
 Organize, update and archive all clinical study documents in the ISF; 
 Confirm that all ICFs are well obtained and available for review; 
 If needed, schedule an appointment for the monitor to visit the pharmacy; 
 If needed, schedule an appointment for the monitor to speak with the PI/investigators;  
 Be available to provide explanations/help when requested by monitor; be available to perform 
corrections in source documents, in the CRF or in other clinical study documents. 
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In these visits, it was possible to clarify questions from all involved parties. If possible, all outstanding issues 
were resolved during these visits. Four to five monitoring visits were appointed, at least, per month. All 
monitoring visits were prepared in advance to ensure that all required documents and files were present 
and organized. 
Coordination of study close out visits 
During my curricular training, I had the opportunity to attend one close out visit. In these visits, monitors 
come to the centres for the final review of regulatory files, SDV and drug accountability reconciliation; to 
resolve all open issues; to ensure that all study records are collected and archived; to collect all study drug, 
equipment and study materials. Some examples of tasks performed by me in the study close out visit that I 
attended are: 
 Arrange a mutually convenient date and time for the monitor to conduct the close out visit; 
 Ensure that all regulatory documentation, source documents and CRF were complete and available 
for review; 
 Give access to all required documents to complete the close out visit to the monitor; 
 Ensure that all queries had been resolved; 
 Inform the monitor of the storage location of study records; 
 Discuss the sponsor’s requirements for subject follow-up for SAE after close out with the monitor; 
 Identify points of contact for new issues that may arise, such as data queries or, if applicable, 
inspections. 
During the curricular training period, I had the opportunity to witness, at least, two close out visits. 
Safeguarding GCP, protocol and applicable laws and regulations’ adherence 
This important task has, as main objective, to ensure study compliance, which is defined, according to 
guideline ICH Topic E 6, as the “adherence to all the trial-related requirements, GCP requirements and the 
applicable regulatory requirements”.2 
All study-related visits, procedures or other clinical interventions should be done in compliance with study 
protocol, GCP requirements and with applicable regulatory requirements. Thus, I had to ensure that no 
protocol deviations were committed. If some unintended protocol deviations or non-compliance with GCP 
requirements or other applicable regulatory requirement occurred, I had to report them to the sponsor in 
order to take the appropriate action designed to prevent the recurrence of the detected deviation. Serious 
and persistent non-compliance by investigator or centre could justify the termination of investigator or 
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centre participation in the clinical study. During the period of my curricular training, a serious or a persistent 
non-compliance never occurred. 
Archiving study documents and maintenance of study documents updated and organised 
During my curricular training, I had the opportunity to maintain and update the study files. When a 
document was missing, it was assumed that it was not collected. For this reason, archiving all documents 
was fundamental to maintain study documentation updated and organized and avoid losing them. All study 
documents should be validated with signature and date and they should be carefully archived in the ISF, in 
the pharmacy file and/or in the patient files. This is mandatory to correctly conduct the study, to rapidly 
find a necessary document and to organize all study documentation to facilitate my daily work, monitoring 
visits and, if applicable, audits/inspection visits. 
All unused files, superseded documents and all documentation from a finished study were stored in the 
Clinical Research Archive. This archive was established on January 2011 and it was developed to store all 
documentation related to clinical research. The clinical research archive is a restricted access room 
equipped with desks, chairs and stationaries. Files from studies already completed/finalized, files from 
studies prematurely stopped or files from studies not approved/started in HIP are all stored in this archive. 
The clinical research archive is also used to store other study material, like study kits or shipment material. 
Prepare study site payments 
A financial agreement is established between the sponsor, the PI and the study site. In this agreement, the 
terms of the conduction of the clinical study and the economic aspects related to the study are 
documented.15 
In specific periods, the sponsor reimbursed the study site/PI, on a completed visit per subject basis and in 
accordance with the budget established in the financial agreement. When the HIP received a new study 
payment, I had to prepare a document where a discrimination of the amount that was transferred was 
presented: indirect costs associated with the payment and subjects and visits that were being reimbursed. 
After that, an Excel document was prepared and sent to the Financial Department of HIP. This Excel 
document contains the distribution of the total amount paid, based on the HIDP rules: indirect costs are 
always taken from the total amount and the remaining value is distributed between the institution (HIDP) 
and the research team. 
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The five tables below (Table 5 to Table 9) present a short description of the twenty clinical trials and the 
four observational studies that I followed during my curricular training, per medical department. Despite 
the fact that this information is available in ClinicalTrials.gov, in this report, study drug name and sponsor 
were not referenced in order to respect the confidential information of studies. The study drug name will 
be replaced by IP. 
For all clinical studies, the first task performed was to carefully read the study protocol and analyse all 
related study documentation. This initial task was aimed to familiarize myself with study objectives, 
procedures and with some study specifications, such as: how to collect study samples, how to handle the 
study drug, and what forms the research team or I should acquire. This first approach was essential to 
coordinate the study appropriately. 
When I began my curricular training, there were already five ongoing clinical trials in cardiology 
department, all from different sponsors: ATLAS 2, TIMI 50, CL3-16257-067, ENGAGE and ATMOSPHERE 
(Table 5). Later, two new clinical trials were proposed to HIP: TRILOGY and CL3-05985-018 (Table 5). All 
seven studies were phase III interventional studies. The new IP or the new combination of drugs was tested 
to treat different conditions. The therapeutic indications are presented in Table 5. 
Table 5. Clinical trials followed in the cardiology department: study acronym, therapeutic indication, study 
intervention and study phase. 
Acronym Condition Intervention Phase 
ATLAS - Acute Coronary Syndrome 
- IP-1 (2.5 and 5 mg) 
- Placebo 
III 
TIMI 50 
- Atherosclerosis 
- Ischemia 
- Myocardial Infarction 
- Cerebrovascular Accident 
- IP-2 
- Placebo 
III 
CL3-16257-067 
- Chronic stable angina 
pectoris 
- IP-3 (2.5, 5 and 7.5 mg)  
- Placebo 
III 
ENGAGE 
- Atrial Fibrillation 
- Embolism 
- Stroke 
- IP-4 
- Placebo 
- Active comparator-1 
III 
ATMOSPHERE - Chronic Heart Failure 
- IP-5 
- IP-6 
- IP-5 + IP-6 
III 
TRILOGY - Acute Coronary Syndrome 
- IP-7 
- IP-8 
- Active comparator-2 
III 
CL3-05985-018 
- Essential arterial 
hypertension 
- IP-9 + IP-11 
- IP-10 + IP-11 
III 
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According to Table 5, considering the first five clinical trials, they had already been approved when I arrived 
at HIP, so, when I began working with these trials they already had included subjects. However, I had also 
the opportunity to randomize subjects using the IVRS or IWRS for these trials. Considering the last two 
trials, they were proposed to be conducted in HIP during my curricular training. Thus, it was possible to 
coordinate their submission process. I followed these trials from their start, which allowed me to follow the 
screening and randomization of all subjects included and, consequently, allowed me to better understand 
the clinical trial since their initiation. 
For ATMOSHERE, TRILOGY and CL3-05985-018, I agreed with the PI to schedule a weekly meeting to resolve 
all outstanding issues. For the other studies, these meetings were not so frequent but they also happened 
at scheduled moments. Beyond the resolution of all outstanding issues, these meetings were also useful to 
discuss subject recruitment, to collect missing documents, to overcome some existing problems, and to 
prepare monitoring visits. 
It was also frequent to receive subject telephone contacts to confirm the date and time of study visits or to 
clarify some questions (e.g. how to use some specific study devices, how to take the study drug). 
Except for the trial CL3-16257-067, I had to access to IVRS or IWRS in all studies to assign the subsequent 
study drug kit numbers. In these transactions, normally, the systems asked me to introduce some subject 
data. The outputs of the systems were the subsequent study drug kit numbers, always accompanied by a 
subject subsequent assignment confirmation fax or e-mail. All information provided by the system was 
registered in the study drug dispensation form and it was forwarded to the pharmacy, where the study 
pharmacist dispensed the study drug. Then, I confirmed the study drug kit numbers on the IVRS/IWRS and 
gave the study drug kits to the PI/sub-investigator. 
For all studies presented in Table 5, I had to: prepare study visits, accompany visits, assign subsequent study 
drug, process and send lab samples, register all required data in CRF and update/archive all documents in 
patient files. For all studies, it was very important to follow the ongoing AE/SAE. 
Regarding ENGAGE study, it was possible to participate in an investigator meeting, named “Re-Engagement 
& Retention Meeting”. This event occurred from 18th of May to 19th of May 2011, in London. The three 
main objectives of this meeting were: 
 Maximize time on drug; 
 Collect data on all subjects; 
 Minimize withdrawn consent and lost to follow-up. 
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During the clinical study initiation activities, sponsor may hold an investigator meeting for a large number of 
study sites. These meetings aim to conduct study protocol and GCP principles training and to allow 
participants an opportunity to ask questions about clinical trial coordination and conduct.
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In oncology department, there were already four ongoing clinical trials (PETACC8, M10-300, SAVE-ONCO 
and TML) and two ongoing observational studies (FOCCO and GIDEON) when I began my curricular training. 
During my curricular training, three new clinical trials (TAGUS, REACH and MUTAR) and two new 
observational studies (REVEAL and SANTARÉM) were approved (Table 6). 
According to Table 6, it is possible to verify that four clinical trials were phase III, two from phase II, one 
from phase IV and the other four were observational studies. These studies were from eight different 
sponsors. Therapeutic indications are presented in Table 6. 
Table 6. Clinical trials and observational studies followed in the oncology department: study acronym, 
therapeutic indication, study intervention and study phase. 
Acronym Condition Intervention Phase 
PETACC8 - Colon cancer 
- IP-12 + IP-13 
- IP-13 
III 
M10-300 
- Advanced Colorectal Cancer 
- Adenocarcinoma of Colon or 
Rectum 
- IP-14 
- Active comparator-3 
- Active comparator-4 
II 
SAVE-ONCO 
- Prevention of Venous 
Thromboembolism 
- Cancer 
- IP-15 
- Placebo 
III 
TML - Colorectal cancer 
- IP-16 + IP-17 /IP-18 or IP-17/IP-19 
- IP-17/IP-18 or IP-17/IP-19 
III 
TAGUS - Metastatic colorectal cancer 
- IP-20 + IP-21 
- IP-21 
II 
REACH - Hepatocellular carcinoma 
- IP-22 
- Placebo 
III 
MUTAR - Non-Small Cell Lung Cancer - IP-23 IV 
FOCCO - Colorectal cancer Observational Study - 
GIDEON - Hepatocellular carcinoma Observational Study - 
REVEAL - Colorectal Cancer Observational Study - 
SANTARÉM - Lung Cancer Observational Study - 
 
Working with clinical trials conducted in oncology department, gave me to the opportunity to work with 
two external imaging clinics. This permitted me to learn how to interpret a computerized tomography 
report, as well as how to interpret the Response Evaluation Criteria In Solid Tumours (RECIST) criteria, 
Version 1.1. RECIST criteria are “a set of published rules that define when cancer patients improve 
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(respond), stay the same (stable) or worsen (progression) during treatments”.28 These criteria are used in 
clinical trials with the aim of achieving a standardized way of assessing tumour response. 
PETACC8 and FOCCO studies had CRF in paper format. Consequently, these were the only studies in which I 
could work with paper CRF. Nowadays, electronic CRF are better accepted and they have been replacing the 
paper CRF. Previously, the CRF pages were usually provided in duplicate. The original pages were monitored 
and collected by the monitor after I had registered all the required data and the copies of these original 
pages remained at the study site. 
I only had the opportunity to assign the subsequent study drug kit numbers using IWRS for M10-300 and 
MUTAR.  
PETACC8, SAVE-ONCO and TML were already in the follow-up period. In this situation, subjects were being 
followed without taking study drug and during this follow-up period, I had to prepare the follow-up visits 
and enter the required information on the CRF.  
In February, it was possible to accompany the study close-out of SAVE-ONCO. In this visit, the monitor and I 
left the ISF organised and with all the requested documentation. ISF, patient files, pharmacy file, laboratory 
manual and all study documentation is identified with study name and is archived and stored in clinical 
research archive for fifteen years (some sponsors accept five to ten years). In these situations the 
administration board and CEIC were notified of the study completion with a formal letter sent to these two 
authorities. 
REVEAL was a retrospective study, so it required a careful analysis of the patient clinic files in order to 
acquire and complete the required data in the CRF.  
With SANTARÉM study, it was possible to work with three clinical scales: EORTC QLQ-C30, EORTC QLQ-C13 
and MASCC antiemetics tool. EORTC QLQ-C30 and EORTC QLQ-C13 are questionnaires developed to assess 
the quality of life of cancer patients.29 MASCC antiemetics tool is a questionnaire used to assess the 
prevention of chemotherapy-induced nausea and vomiting.
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For all the clinical trials presented in Table 6, except TAGUS and REACH, I had to: prepare study visits, 
accompany visits, assign subsequent study drug, process and send lab samples, register all required data in 
the CRF and update/archive all documents in patient files. For observational studies, I prepared the study 
visits, registered all required data in CRF and archived the documents in patient files. For all studies it was 
very important to follow the ongoing AE/SAE. 
In endocrinology department, there was already one ongoing clinical trial: BI 1245.33. During my training, 
no more clinical trials were initiated in this department (Table 7). 
BI 1245.33 was a phase IIb clinical trial to treat patients with type 2 Diabetes. 
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Table 7. Clinical trials followed in the endocrinology department: study acronym, therapeutic indication, 
study intervention and study phase. 
Acronym Condition Intervention Phase 
BI 1245.33 - Type 2 Diabetes - IP-24 (10 and 25 mg) 
- Placebo 
IIb 
 
The tasks I performed in this trial were to: prepare study visits, accompany visits, assign subsequent study 
drug, process and send lab samples, register all required data in CRF and update/archive all documents in 
patient files. It was also very important to follow the ongoing AE/SAE. 
Regarding the infectious diseases department, I had the opportunity to follow two clinical trials, since their 
start: BI 1241.21 and BI 1220.30 (Table 8). Both clinical trials were intended to treat chronic hepatitis C; one 
was phase II and the other phase III. 
Table 8. Clinical trials followed in the infectious diseases department: study acronym, therapeutic 
indication, study intervention and study phase. 
Acronym Condition Intervention Phase 
BI 1241.21 - Chronic Hepatitis C 
- IP-25 and IP-26 
- Active comparator-5 and active 
comparator-6 
II 
BI 1220.30 - Chronic Hepatitis C 
- IP-27 
- Active comparator-5 and active 
comparator-6 
III 
 
The tasks I performed in this clinical trial were to: prepare study visits, accompany visits, assign subsequent 
study drug, process and send lab samples, register all required data in CRF and update/archive all 
documents in patient files. 
These two clinical trials gave me the opportunity to work with the infectious diseases department and with 
studies in the virology area. 
With BI 1241.21 and BI 1220.30, I was faced with new challenges: 
 Greater number of collection/transfer tubes – Usually, for other studies, the collection tubes never 
exceeded five tubes. In these trials, the collection tubes were about fifteen tubes per subject. For 
each type of tube/intended analysis the centrifugation process required different conditions: 
different revolutions per minute, different times of centrifugation and different times for blood 
clotting. This required me to carefully follow the lab/requisitions instructions when I was 
processing samples; 
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 More than one subject per day – This required me to carefully identify all subject documentation 
and lab materials; to grab attention when I was processing samples, that is, to grab my attention 
when I was transferring the plasma to transfer tubes, in order not to change the tubes and/or 
subjects; 
 Frequent study visits – At some stages of these trials, subjects had to visit the centre more than 
once per week and this required that all documentation, patient files and CRF were updated and 
organised. 
For these two studies, I had to: prepare study visits, accompany visits, process and send lab samples, 
register all required data in CRF and update/archive all documents in patient files. In these studies, I did not 
assign the subsequent study drug kit numbers because investigators were responsible for that task. For all 
studies, it was very important to follow the ongoing AE/SAE. 
Study BI 1220.30 was audited in HIP. During my curricular training, I had the opportunity to follow and help 
the preparation for the audit. An audit is, according to guideline ICH Topic E 6, “a systematic and 
independent examination of trial related activities and documents to determine whether the evaluated trial 
related activities were conducted, and the data were recorded, analysed and accurately reported according 
to the protocol, sponsor's standard operating procedures (SOP), Good Clinical Practice (GCP), and the 
applicable regulatory requirement(s)”.2 To prepare the audit, all patient files were organised and all subject 
related documents/forms were carefully archived; all required data was entered on the CRF and all open 
queries were resolved; the study drug dispensing logs were updated and the study drug accountability and 
compliance were performed; all missing study related documents were collected and archived; and the ISF 
was organised and updated. 
In the rheumatology department, I had the possibility to follow a study program – OSKIRA Programme. This 
program was composed by three clinical trials: OSKIRA-2, OSKIRA-3 and OSKIRA-X (Table 9). These three 
trials were focused on the treatment of rheumatoid arthritis and they were all phase III.  
Table 9. Clinical trials followed in the rheumatology department: study acronym, therapeutic indication, 
study intervention and study phase. 
Acronym Condition Intervention Phase 
OSKIRA 
Programme 
OSKIRA-2 
- Rheumatoid Arthritis 
- IP-28 
- Placebo 
III 
OSKIRA-3 
- IP-28 
- Placebo 
III 
OSKIRA-X - IP-28 III 
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At the end of my curricular training, subject enrolment process was not yet initiated. Thus, for these three 
trials, I just prepared study visit scripts, studied drug dispensation forms and nurse forms.  
Regarding this study program, it was possible to participate in an investigator meeting, named “OSKIRA 
Programme”. This event occurred from 6th of December to 8th of December 2010, in Barcelona. Its 
programme was composed by eleven themes: study protocols overview; medical monitoring, 
communication and surveillance; clinical monitoring; ICH-GCP guidelines; randomization and drug supply 
management via IVRS; IP management; central lab, imaging lab; AE reporting; cardiovascular events; and 
patient recruitment. 
Meeting objectives were to: 
 Provide the research teams with the rationale behind the OSKIRA Programme; 
 Present a detailed understanding of the study protocol and the clinical research procedures that 
govern the study; 
 Give the research teams an opportunity to interact with their colleagues and different study teams; 
 Communicate the patient recruitment plan and to discuss best practice for patient recruitment and 
retention. 
This was undoubtedly a very enriching experience. With this exhaustive explanation of study specifications 
and procedures, study teams became more able to correctly conduct a trial in their study sites, as they 
received training for the study by expert professionals and they had the opportunity to expose their 
particular questions. 
At the end of my curricular training, on 30th of June 2011, three new clinical trials were approved by HIP 
administration board: DIGEST, BI 1220.7 and BI 1220.48. For these trials, I only worked in their formal 
approval process. 
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Chapter 4: Discussion 
When I began my training, ten clinical trials and two observational studies were already on-going at HIDP. 
During the training, ten new clinical trials and two new observational studies were approved by HIDP and 
were started. When my curricular training finished, three new clinical trials were approved. Sponsors see in 
HIP a potential clinical study site for three main reasons: (1) motivated and qualified staff; (2) adequate 
facilities and (3) adequate equipment and materials. 
The creation of the clinical research archive was, frankly, one of the biggest endeavours of TRS. It allows us 
to efficiently archive all study binders. In the future, the creation of a documental management system will 
be important to guarantee the adequate files archiving/traceability. 
During my curricular training, I identified some opportunities for improvement, as described below: 
 Obtainment of ICF – The main errors detected in the ICF obtainment process are: incorrect ICF 
version provided to subjects and incorrect/incomplete filling of ICF. To correct these problems, I 
always confirmed the ICF version, as well as, the adequate completion of all fields. 
 Subject recruitment – Nowadays, meeting the subject recruitment objectives is one of the main 
problems to overcome in Portuguese clinical research. This problem is justified for several reasons: 
patients that refuse to participate (cultural issues, family influence, unavailability); per 
investigator/site conditions (very optimistic estimative, demotivated research team, unavailability, 
inadequate logistic, internal conflicts); and per study protocol conditions (difficult study design, 
restricted inclusion/exclusion criteria, study procedures incompatible with clinic practice, very 
complex study procedures). So, to meet subject recruitment objective, I defined with investigators 
a pre-selection list of potential subjects at the beginning of the study, I recorded all selected 
subjects, as well as all screening failures and the exclusion motive identified. Databases search, 
such as patient hospital files or SAM application, was also a valid strategy that I adopted to 
improve recruitment. 
 Study procedures – One of the most frequent problems detected during the study conduction is 
the failure to comply with study procedures required by the protocol. Thus, to overcome this 
situation, I always prepared study visits in advance. On the other hand, some study procedures 
are not performed within the time period established by protocol. So, I also scheduled study visits 
in advance to ensure that both parties, investigator and participant, will be available for the 
appointment. 
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 Clinical records – Incomplete, incorrect and, sometimes, the non-existence of clinical records are 
also frequently noticed. In clinical research it is often said "what is not written does not exist”, so 
all study-related interventions, consultations or procedures reports should be recorded in patient 
files.. This problem comprises, as examples, the absence or incomplete source documents; 
minimalistic medical histories; AE/SAE records; concomitant medications. To overcome this 
problem I prepared supporting documents for data collection: checklists, study visit scripts, nurse 
forms, among others. 
 AE/SAE notification – Usually, investigators tend to undervalue the events experienced by subjects 
– under-reporting. On the other hand, investigators fail to comply with reporting deadlines. Once 
again, I prepared support documents for the collection of AE/SAE information. 
 Research team responsibilities – In this situation, I highlighted the delegation on unqualified 
personnel and personnel performing study procedures without having been delegated. This means 
that people who were performing study procedures were not familiarized with study protocol and, 
most likely, protocol deviations will occur. At the beginning of the trial, the delegation log should 
be consciously filled and all research team should receive training for the study. I remembered all 
research team in advance for the study appointments, in order to certify that all elements were 
available to perform their delegated activities. 
During my curricular training, all health professionals of HIP have accepted my presence well and they have 
welcomed me as a collaborator of HIP, appreciating my work and entrusted me with responsibilities. 
However, I am faced with some difficulties: 
 Managing many study visits at the same time – It happened frequently that study visits were 
scheduled for the same day. Managing many study visits at the same day/time became a 
complicated task, especially when they are from different studies. Whenever possible, study visits 
were scheduled for different days or, if it was not possible, for different times. In any case, when 
study visits coincided, I ensured that, at least, all required study procedures were complied. This 
exercise helped me to be more organised (developing a calendar of activities/tasks to accomplish 
in each day) and to prioritize more important and urgent tasks. 
 Communication and linguistic skills – One of the biggest barriers that I faced was the use of English 
as the universal language. I had to use the English language in several occasions: to 
talk/communicate with sponsor, to contact with helpdesks, to activate my CRF/IVRS/IWRS access 
codes, to fill the CRF, to answer queries, among others. It was a good exercise that helped me 
improve my communication and linguistic skills. 
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 Personal and interpersonal skills – Due to my personal characteristics, the first contact with new 
people was another barrier that I had to overcome during the curricular training. At the beginning 
of the training, this difficulty was more evident because of the fear on how I would be received. At 
the end of the curricular training, this fear had diminished and the approach with other people was 
made in a more natural and spontaneous way. 
Despite the highlighted difficulties, this was a very enriching training for many reasons. This training gave 
me the opportunity to: 
 Better know the applicable laws and regulations better and to know how to apply them in my daily 
work; 
 Apply the knowledge and tools acquired during the Master’s degree; 
 Work with different health professionals, with different backgrounds and expertise; 
 Work with different sponsors and monitors; 
 Work with a great diversity of trials, this is, trials with different study drugs, different therapeutic 
indications, different study phases, different specificities; 
 Perform accompanied work and then to work autonomously; 
 Improve my personal, interpersonal, social, search and linguistic skills. 
47 
 
Chapter 5: Conclusions 
Clinical research is absolutely essential to enhance progress in the health area. All elements of a research 
team are fundamental to study success and study coordinators are no exception.  
The roles of the study coordinator are not perfectly defined yet. They are usually associated with data 
collection, but the contributions of these study elements can be far more extensive.  
During the training, I had the possibility to follow all activities performed before, during and after the 
submission of a clinical trial to regulatory authorities. So, I believe that all curricular training objectives were 
fully achieved. 
This was a very enriching curricular training for several reasons: gradual increase in autonomy (autonomous 
work); possibility to work with clinical trials in different interventional phases, different therapeutic 
indications and different required information/documents; possibility to work with different health 
professionals (physicians, pharmacists, nurses, laboratory technicians, diagnosis and therapeutic 
technicians) with different backgrounds and expertise; and possibility to work with different sponsors and 
monitors. 
During the curricular training, I had the opportunity to perform a wide range of activities that were very 
useful to my growth as a professional. Being a study coordinator allowed me to apply all knowledge and 
tools acquired during the Master’s degree and, especially, it allowed me to learn how to proceed in real 
work situations. Additionally, it was possible to identify my particular areas of interest, as well as to 
establish a working contacts network. 
I have been invited to remain in HIP, continuing my functions as a clinical study coordinator. I really 
appreciated my journey in HIP and I am very thankful for the opportunity to remain a collaborator of this 
institution. 
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